Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?
Reenaers
C
C
Belaiche
J
J
Louis
E
E
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003345:Corticosterone / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D055985:Latent Tuberculosis / Q000000981:diagnostic imaging / Q000276:immunology*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011859:Radiography; D014397:Tuberculosis, Pulmonary / Q000000981:diagnostic imaging / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D001379:Azathioprine; D003345:Corticosterone; D008727:Methotrexate